Characterisation of the human NMDA receptor subunit NR3A glycine binding site (Q24298287)

GOA release 2020-03-11

glycine binding

1 reference

GOA release 2020-03-11

E Benedikz

Benedikz

1 reference

9 December 2023

A Nilsson

Nilsson

1 reference

9 December 2023

J Duan

series ordinal

author given names

author last names

Duan

1 reference

9 December 2023

L-L Mo-Boquist

series ordinal

author given names

L-L

author last names

Mo-Boquist

1 reference

9 December 2023

E Sundström

series ordinal

author given names

author last names

Sundström

1 reference

Temporal and regional expression of NMDA receptor subunit NR3A in the mammalian brain

9 December 2023

language of work or name

English

0 references

publication date

March 2007

0 references

0 references

0 references

0 references

1151-9

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Evolutionary trace analysis of ionotropic glutamate receptor sequences and modeling the interactions of agonists with different NMDA receptor subunits

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Cell surface expression of the human N-methyl-D-aspartate receptor subunit 1a requires the co-expression of the NR2A subunit in transfected cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Selective modulation of NMDA responses by reduction and oxidation

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Nitric oxide-induced blockade of NMDA receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Mutational analysis of the glycine-binding site of the NMDA receptor: structural similarity with bacterial amino acid-binding proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

The function of the amino terminal domain in NMDA receptor modulation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

NR3A NMDA receptor subunit mRNA expression in schizophrenia, depression and bipolar disorder

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Expression of a soluble glycine binding domain of the NMDA receptor in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

How well can molecular modelling predict the crystal structure: the case of the ligand-binding domain of glutamate receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Cloning and characterization of a novel NMDA receptor subunit NR3B: a dominant subunit that reduces calcium permeability.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Cloning and expression of the human N-methyl-D-aspartate receptor subunit NR3A

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand binding core

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Molecular Recognition of Protein−Ligand Complexes: Applications to Drug Design

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Molecular modeling of the ligand-binding domains of the NR3A and NR3B subunits of the NMDA receptor.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Proton inhibition of N-methyl-D-aspartate receptors in cerebellar neurons

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Subunit arrangement and function in NMDA receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Activation of NR1/NR2B NMDA receptors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Recombinant human NMDA homomeric NR1 receptors expressed in mammalian cells form a high-affinity glycine antagonist binding site

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Enantiomers of HA-966 (3-amino-1-hydroxypyrrolid-2-one) exhibit distinct central nervous system effects: (+)-HA-966 is a selective glycine/N-methyl-D-aspartate receptor antagonist, but (-)-HA-966 is a potent gamma-butyrolactone-like sedative

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

The NR2B-specific interactions of polyamines and protons with the N-methyl-D-aspartate receptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Regulation of NR1/NR2C N-methyl-D-aspartate (NMDA) receptors by phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

The tetrameric structure of a glutamate receptor channel

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Expression of the NR3A subunit of the NMDA receptor in human fetal brain

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Characterization of a soluble ligand binding domain of the NMDA receptor regulatory subunit NR3A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

NMDA channel behavior depends on agonist affinity

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Cloning and characterization of chi-1: a developmentally regulated member of a novel class of the ionotropic glutamate receptor family

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Developmental and regional expression pattern of a novel NMDA receptor-like subunit (NMDAR-L) in the rodent brain

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Evidence for a tetrameric structure of recombinant NMDA receptors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Assembly with the NR1 subunit is required for surface expression of NR3A-containing NMDA receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

An NMDA receptor ER retention signal regulated by phosphorylation and alternative splicing.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

Studies of NMDA receptor function and stoichiometry with truncated and tandem subunits.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROPHARM.2006.12.002

7 January 2021

10.1016/J.NEUROPHARM.2006.12.002

Identifiers

DOI

0 references

Fatcat ID

release_qyl34qjegbckvkuvjixg2vrfl4

0 references